Fosamax and Osteonecrosis of the Jaw: What Studies Show About Causation and Risk

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Focused Risk Assessment

The legacy of general health and science information has long provided a foundation for public understanding of medical conditions and therapeutic options. Within this broad context, discussions of medication benefits and potential adverse effects have been framed for a diverse audience, emphasizing balanced awareness without delving into specialized mechanistic details. This heritage serves as a starting point for examining how certain pharmaceutical exposures may intersect with specific health outcomes in defined populations. Transitioning from this general health perspective, a focused occupational exposure concern emerges when considering the relationship between bisphosphonate use, such as Fosamax, and the risk of osteonecrosis of the jaw. While the general health context addresses medication risks for the average patient, occupational settings may involve distinct exposure patterns, including higher cumulative doses or prolonged administration in clinical or industrial environments. This pivot reframes the inquiry from a broad patient education model to a more targeted assessment of exposure scenarios where the frequency and intensity of bisphosphonate contact could differ from standard therapeutic use. The shift acknowledges that understanding risk requires examining not only the drug’s effects in routine care but also the potential implications for individuals with elevated or repeated exposure in occupational roles.

Understanding Fosamax and Its Association with Osteonecrosis of the Jaw

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its use has been associated with osteonecrosis of the jaw (ONJ), a condition characterized by exposed, non-healing bone in the maxillofacial region. The clinical presentation of ONJ can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Mechanistic Pathways and Risk Factors

The mechanistic pathways linking Fosamax to ONJ involve the drug's antiresorptive action on bone metabolism. Bisphosphonates like alendronate inhibit osteoclast-mediated bone resorption, which can lead to suppressed bone turnover. A multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This suggests that the unique structure and physiology of the jawbone may make it particularly susceptible to the effects of bisphosphonate therapy, potentially contributing to the development of ONJ. Regarding the timeline between exposure and documented harm, the time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of FOSAMAX, the percentages of patients with these symptoms were similar in the FOSAMAX and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a subset of patients had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Duration of Exposure and Quantitative Risk Estimates

The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). A cohort study among cancer-free female patients aged 40-89 with, or at risk for, osteoporosis in the United Kingdom Clinical Practice Research Datalink found that ONJ risk was threefold higher after 2-3 years of treatment and eightfold after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702/). Absolute risks remained low, approximately 0.05% after 5 years, and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/).

Adequacy of Warnings and Causation Considerations

The adequacy of warnings regarding Fosamax and ONJ is addressed in the prescribing information. The label includes a specific warning under section 5.4, "Osteonecrosis of the Jaw," which states that ONJ has been reported in patients taking bisphosphonates, including FOSAMAX (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label also notes that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Additionally, the label advises discontinuation of use if severe symptoms develop, and notes that most patients had relief of symptoms after stopping (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Causation-related considerations for affected patients involve evaluating the temporal relationship between Fosamax exposure and the development of ONJ, as well as the presence of other risk factors. The label acknowledges that ONJ can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk may be increased by duration of exposure, and discontinuation of treatment may reduce risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The cohort study data indicate that absolute risks remain low, but the relative risk increases with longer treatment duration (https://pubmed.ncbi.nlm.nih.gov/39400702/). For patients who develop ONJ, the label notes that most had relief of symptoms after stopping the drug, though a subset experienced recurrence upon rechallenge (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In summary, the evidence supports a causal association between Fosamax use and osteonecrosis of the jaw, with risk increasing with duration of exposure. The prescribing information provides warnings and guidance for management, including discontinuation of treatment in patients with severe symptoms or those undergoing invasive dental procedures. Affected patients should consider the temporal relationship, duration of use, and presence of other risk factors when evaluating causation.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the association between Fosamax and osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate medication that has been associated with osteonecrosis of the jaw (ONJ), a condition characterized by exposed, non-healing bone in the maxillofacial region. The prescribing information includes a specific warning about this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

How does the duration of Fosamax use affect the risk of ONJ?

The risk of ONJ increases with longer duration of bisphosphonate exposure. A cohort study found that the risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702/). Absolute risks remain low, approximately 0.05% after 5 years.

What are the known risk factors for developing ONJ while taking Fosamax?

Known risk factors include invasive dental procedures (e.g., tooth extraction, dental implants), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and pre-existing dental disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

What does the prescribing information say about managing ONJ risk?

The label advises that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk of ONJ. It also recommends stopping the drug if severe symptoms develop, noting that most patients experience relief after discontinuation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.